Maryam Alasfour

Dr. Maryam Alasfour

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 October 2024 in Cancers
Verified
Journal Article
Open access
PDF file
ABAndres Bravo-Gonzalez
Andres Bravo-Gonzalez
MAMaryam Alasfour
Maryam Alasfour
DSDeborah Soong
Deborah Soong
JNJose Noy
Jose Noy
GPGeorgios Pongas
Georgios Pongas
B-cell lymphoid malignancies are a heterogeneous group of hematologic cancers, where Bruton’s tyrosine kinase (BTK) inhibitors have received FDA approval for several subtypes. The first-in-class covalent BTK inhibitor, Ibrutinib, binds to the C481 amino acid residue to block the BTK enzyme and prevent the downstream signaling. Resistance to covalent BTK inhibitors (BTKi) can occur through mutations at the BTK binding site (C481S) but also other BTK sites and the phospholipase C gamma 2 (PLCγ2) resulting in downstream signaling. To bypass the C481S mutation, non-covalent BTKi, such as Pirtobrutinib, were developed and are active against both wild-type and the C481S mutation. In this review, we discuss the molecular and genetic mechanisms which contribute to acquisition of resistance to covalent and non-covalent BTKi. In addition, we discuss the new emerging class of BTK degraders, which utilize the evolution of proteolysis-targeting chimeras (PROTACs) to degrade the BTK protein and constitute an important avenue of overcoming resistance. The moving landscape of resistance to BTKi and the development of new therapeutic strategies highlight the ongoing advances being made towards the pursuit of a cure for B-cell lymphoid malignancies.

18 February 2024 in Cancers
Verified
Journal Article
Open access
PDF file
ASAli Al Sbihi
Ali Al Sbihi
MAMaryam Alasfour
Maryam Alasfour
GPGeorgios Pongas
Georgios Pongas
Chemoimmunotherapy and cellular therapy are the mainstay of the treatment of relapsed/refractory (R/R) lymphomas. Development of resistance and commonly encountered toxicities of these treatments limit their role in achieving desired response rates and durable remissions. The Antibody–Drug Conjugate (ADC) is a novel class of targeted therapy that has demonstrated significant efficacy in treating various cancers, including lymphomas. To date, three ADC agents have been approved for different lymphomas, marking a significant advancement in the field. In this article, we aim to review the concept of ADCs and their application in lymphoma treatment, provide an analysis of currently approved agents, and discuss the ongoing advancements of ADC development.

14 July 2025 in Blood Advances
Verified
Journal Article
Open access
GPGeorgios Pongas
Georgios Pongas
MAMaryam Alasfour
Maryam Alasfour
DCDaniel P. Cassidy
Daniel P. Cassidy
JAJuan Pablo Alderuccio
Juan Pablo Alderuccio
JRJoseph David Rosenblatt
Joseph David Rosenblatt
ILIzidore S Lossos
Izidore S Lossos

18 July 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
ABAndres Bravo-Gonzalez
Andres Bravo-Gonzalez
MAMaryam Alasfour
Maryam Alasfour
DSDeborah Soong
Deborah Soong
JNJose Noy
Jose Noy
GPGeorgios Pongas
Georgios Pongas
B-cell lymphoid malignancies is a heterogeneous group of hematologic cancers, where Bruton's tyrosine kinase (BTK) inhibitors have received FDA approval for several subtypes. The first-in-class covalent BTK inhibitor, ibrutinib, binds to the C481 amino acid residue to block the BTK enzyme and prevent the downstream signaling. Resistance to covalent BTK inhibitors can occur through mutations at the BTK binding site (C481S) but also other BTK sites and the phospholipase C gamma 2 (PLCγ2) resulting in downstream signaling. To bypass the C481S mutation, non-covalent BTK inhibitors, such as pirtobrutinib, were developed and are active against both wild-type and the C481S mutation. In this review, we discuss the molecular and genetic mechanisms which contribute to acquisition of resistance to covalent and non-covalent BTK inhibitors. In addition, we discuss the new emerging class of BTK degraders, which utilize the evolution of proteolysis-targeting chimeras (PROTACs) to degrade the BTK protein and constitute an important avenue of overcoming resistance. The moving landscape of resistance to BTK inhibitors and the development of new therapeutic strategies highlight the ongoing advances, that are being made towards the pursue of cure of B-cell lymphoid malignancies.